{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-006782","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.828285+00:00","generated_at":"2026-06-18T09:16:40.974642+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cumberland Pharma reports 17% revenue growth to $42M in FY2022; adj. EPS $0.14","bullets":["FY2022 revenue $42.0M (+17% YoY); net loss $5.6M ($0.38/sh); adj. earnings $2.1M ($0.14/sh) vs adj. loss $1.2M in 2021.","Q4 revenue $9.1M; net loss $2.4M; adj. loss $0.7M ($0.05/sh) vs adj. loss $1.9M in Q4 2021.","Cash from operations $8.5M vs $6.3M prior year; balance sheet: $20M cash, $57M liabilities, $36M equity.","Product revenue: Kristalose $15.2M, Sancuso $13.2M, Vibativ $7.5M, Caldolor $4.8M.","Acquired Sancuso from Kyowa Kirin in 2022; new Nashville HQ; international partnerships for Vibativ and Caldolor."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-006782","json":"https://secwatch.observer/filing/0001628280-23-006782.json","markdown":"https://secwatch.observer/filing/0001628280-23-006782.md","text":"https://secwatch.observer/filing/0001628280-23-006782.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023006782/0001628280-23-006782-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023006782/cpix-20230307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:16:40.974642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc8e58fc3f8589c565986533d776ff47a48f1449","claim":"CUMBERLAND PHARMACEUTICALS INC reported full year 2022 results: revenue Net revenues were $42.0 million, net income Net loss for the fourth quarter of 2022 was $2.4 million, and $5.6 million, or $0.38 per share, for the year., EPS $0.38 per share.","evidence_excerpt":"(NASDAQ: CPIX) , a specialty pharmaceutical company today announced full year 2022 financial results and provided a Company update. Net revenues grew 17% over the prior year to $42 million, resulting in $8 million in cash flow from operations. As of December 31, 2022, the Company's total assets were $93 million, including $20 million in cash. Total liabilities were","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023006782/0001628280-23-006782-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"Net revenues were $42.0 million"},{"label":"Net income","value":"Net loss for the fourth quarter of 2022 was $2.4 million, and $5.6 million, or $0.38 per share, for the year."},{"label":"EPS","value":"$0.38 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}